To stop or not to stop an asthma biologic, that is the question
| dc.contributor.author | Philipenko, Brianne S. | |
| dc.contributor.author | Davis, Beth | |
| dc.contributor.author | Cockcroft, Donald W. | |
| dc.date.accessioned | 2024-09-19T16:34:23Z | |
| dc.date.available | 2024-09-19T16:34:23Z | |
| dc.date.issued | 2024-09 | |
| dc.description | Accepted manuscript CC BY-NC-ND https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en | |
| dc.description.abstract | During a time when anti-asthma biologics are readily accessible, the article by Brightling et al1 in the current issue provides additional much needed evidence to discuss with patients with severe asthma when the inevitable question arises of “How long do I need to continue on my asthma biologic therapy?” With now 6 biologics available, including most recently tezepelumab that can be prescribed without biomarker restrictions, it has become increasingly easy to prescribe these medications. After achieving good asthma control, physicians are left to contemplate the question of “now what?” Are these medications lifelong therapies? | |
| dc.description.version | Peer Reviewed | |
| dc.identifier.citation | Philipenko, B. S., Davis, B., & Cockcroft, D. W. (2024). To stop or not to stop an asthma biologic, that is the question. Annals of Allergy, Asthma & Immunology, 133(3), 236–237. https://doi.org/10.1016/j.anai.2024.06.012 | |
| dc.identifier.doi | 10.1016/j.anai.2024.06.012 | |
| dc.identifier.uri | https://hdl.handle.net/10388/16060 | |
| dc.language.iso | en | |
| dc.publisher | Elsevier | |
| dc.rights | Attribution-NonCommercial-NoDerivs 2.5 Canada | en |
| dc.subject | asthma control | |
| dc.subject | biologic therapy | |
| dc.subject | tezepelumab | |
| dc.title | To stop or not to stop an asthma biologic, that is the question | |
| dc.type | Article |